Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What target expansions do you use when treating with 60Gy in 15 fractions for lung?
Related Questions
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
